Ottobock SE & Co. KGaA
ISIN: DE000BCK2223
WKN: BCK222
19 June 2026 11:30AM

EQS-News: Ottobock sells its Human Mobility wheelchair business

Ottobock SE & Co. KGaA · ISIN: DE000BCK2223 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2349470

EQS-News: Ottobock SE & Co. KGaA / Key word(s): Disposal/Strategic Company Decision
Ottobock sells its Human Mobility wheelchair business

19.06.2026 / 11:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Ottobock sells its Human Mobility wheelchair business

Ottobock sharpens its strategic focus on its core business / DHCare invests in the expansion of its European business

Duderstadt, June 19, 2026
 

Publicly listed global MedTech company Ottobock SE & Co. KGaA signed an agreement on June 19, 2026 to sell its Human Mobility business unit to the international medical technology company DHCare. The transaction is expected to close in H2/2026.

With the sale, Ottobock is consistently continuing its strategic focus on its core business. In the future, the company will concentrate even more strongly on the areas where it sees the greatest growth potential, particularly prosthetics and neuro-orthotics.

Oliver Jakobi, CEO of Ottobock SE & Co. KGaA, said: “By selling our wheelchair business, we are sharpening our strategic focus on our core business. At the same time, with DHCare we have found the right investor for Human Mobility. The team has built a technologically leading business with strong clinical credibility and close customer relationships. We are convinced that Human Mobility has the best opportunities for growth in its new environment.”

A strategic step with a clear perspective

With DHCare, Human Mobility gains a new owner with a broad European footprint and a complementary portfolio. Human Mobility contributes, above all, its strong position in the DACH region and its expertise in complex powered wheelchairs.

Graham Ewart, CEO of DHCare, said: “This acquisition is an important milestone for DHCare. It is our first under the new ownership structure and our first as a combined platform. With Ottobock Human Mobility, we are taking another significant step in expanding our position as a leading provider of mobility solutions in Europe — with high-quality, clinically proven solutions as well as technical support and high-level after-sales service.”

Secured transition for employees and market partners

As part of the transaction, the German Human Mobility companies as well as Dutch pediatric wheelchair specialist veldink4Kids will transfer in full to the new group.

For users, payers, service providers and specialist retailers alike, Ottobock will remain a reliable partner until the transaction is completed.

Dr. Arne Kreitz, CFO of Ottobock SE & Co. KGaA, said: “By divesting this non-core business area, we are continuing to sharpen our focus on expanding high-growth and highly innovative businesses. At the same time, it is important to us to ensure an orderly and reliable transition for the employees and locations affected, as well as for customers and partners. In DHCare, we have found a partner that wants to further develop Human Mobility within a strong European mobility environment.”

Note: In connection with this transaction, the French subsidiaries of both groups have entered into exclusive negotiations for the sale of the French Human Mobility business, and the relevant employee information and consultation processes will be initiated shortly.
 

Media Contact:

Ottobock SE & Co. KGaA
Merle Florstedt
Head of Corporate Communications
Mobile +49 151 441 616 25
Merle.florstedt@ottobock.de 

 

Investor Relations Contact:

Ottobock SE & Co. KGaA
Julia Hartmann
VP Investor Relations
Mobile: +49 151 556 848 07
Julia.Hartmann@ottobock.de

 

About Ottobock

Ottobock, a listed global MedTech champion, combines over 100 years of tradition with outstanding innovative strength in the fields of prosthetics, neuro-orthotics and exoskeletons. Ottobock develops innovative fitting solutions for people with limited mobility and is driving the digitalization of the industry. Founded in Berlin in 1919, the company has business activities in 45 countries with nearly 9,300 employees (FTEs) worldwide and operates the largest international patient care network with around 420 patient care clinics. Ottobock is shaping the future of human bionics with a strong R&D ratio in the products and components business and over 2,600 patents and patent applications. Ottobock’s mission of improving freedom of movement, quality of life and independence is deeply rooted in the company's DNA, as is its social commitment: Ottobock has been a partner and supporter of the Paralympics since 1988. 

 

About DHCare

DHCare is a global medical device company that supports efforts to move health forward by delivering innovative and leading solutions for individuals whose lives are impacted by reduced movement.

We strive to constantly support our healthcare partners, and the people whose healthcare needs they serve, working to keep improving the vital connections between movement and health, enabling accelerated recovery and healthy independence in daily living.

 



19.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Ottobock SE & Co. KGaA
Max-Näder-Straße 15
37115 Duderstadt
Germany
Phone: +49 5527 848 - 0
E-mail: info@ottobock.com
Internet: https://corporate.ottobock.com
ISIN: DE000BCK2223
WKN: BCK222
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX; Vienna Stock Exchange
EQS News ID: 2349470

 
End of News EQS News Service

2349470  19.06.2026 CET/CEST

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2020 2021 2022 2023 2024 2025 2026e
Sales1 0,00 1.187,51 1.333,19 1.495,04 1.604,60 1.679,80 1.790,00
EBITDA1,2 0,00 162,12 1.963,35 248,70 299,20 371,80 440,00
EBITDA-Margin3 0,00 0,00 14,85 16,64 18,65 22,13 24,58
EBIT1,4 0,00 0,00 -934,00 -27,00 290,00 0,00 256,00
EBIT-Margin5 0,00 0,00 0,00 -1,81 18,07 11,07 14,30
Net Profit (Loss)1 0,00 19,63 75,33 48,10 27,90 88,30 140,00
Net-Margin6 0,00 0,00 5,64 3,22 1,74 5,26 7,82
Cashflow1,7 0,00 0,00 82,00 197,80 275,10 333,20 0,00
Earnings per share8 0,00 0,00 1,17 0,75 0,44 1,44 2,10
Dividend per share8 0,00 0,00 0,00 0,00 0,00 0,97 1,05
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Ottobock
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
BCK222 DE000BCK2223 SE & Co. KGaA 3.218,71 Mio € 09.10.2025 9F3GG68Q+78
* * *
PE 2027e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
20,96 23,95 0,88 38,69 9,81 9,66 1,92
Dividends
Dividend '2023
in €
Dividend '2024
in €
Dividend '2025e
in €
Div.-Yield '2025e
in %
0,00 0,00 0,97 1,93%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
19.05.2026 06.05.2026 13.08.2026 12.11.2026 19.03.2026
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-2,33%
50,30 €
ATH 76,35 €
-9,48% +0,00% -22,91% +0,00% -23,79%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2026          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2026 by Gereon Kruse #BGFL